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The crystal structure of acetylcholine-binding protein
(AChBP) from the mollusk Lymnaea stagnalis is the es-
tablished model for the ligand binding domains of the
ligand-gated ion channel family, which includes nico-
tinic acetylcholine, 5-hydroxytryptamine (5-HT3), -ami-
nobutyric acid (GABA), types A and C, and glycine re-
ceptors. Here we present the crystal structure of a
remote homolog, AChBP from Bulinus truncatus, which
reveals both the conserved structural scaffold and the
sites of variation in this receptor family. These include
rigid body movements of loops that are close to the
transmembrane interface in the receptors and changes
in the intermonomer contacts, which alter the pentamer
stability drastically. Structural, pharmacological and
mutational analysis of both AChBPs shows how 3 amino
acid changes in the binding site contribute to a 5–10-fold
difference in affinity for nicotinic ligands. Comparison
of these structures will be valuable for improving struc-
ture-function studies of ligand-gated ion channel recep-
tors, including signal transduction, homology modeling,
and drug design.
Nicotinic acetylcholine receptors (nAChRs)1 are members of
the pentameric ligand-gated ion channel (LGIC) family that
mediate and/or modulate synaptic signaling (1). nAChRs play
important roles in memory and learning processes (2), and
absence of functional receptors is associated with multiple dis-
eases including schizophrenia, Alzheimer disease, drug addic-
tion, and the autoimmune disease myasthenia gravis (3).
nAChRs are also involved in nicotine addiction in tobacco
smokers (4). Taken together, these receptors have prominent
roles in disease of the nervous system and are now major
targets in drug discovery programs.
nAChRs can be divided into muscular nicotinic receptors,
which are found at the neuromuscular junction and have
(1)21 subunit stoichiometry, and neuronal nAChRs, which
exist as homopentameric (e.g. 7) or various heteropentameric
(e.g. 24) protein assemblies. To date 10 - and 4-nAChR
subunits have been identified in vertebrates that generate a
large diversity of nAChRs with distinct pharmacological and
ligand binding characteristics. nAChRs are composed of an
N-terminal extracellular ligand binding domain and a trans-
membrane region that forms the ion channel. Agonist binding
stabilizes the open state of the channel and allows ions to pass
through the pore (5). Ligand-binding sites are localized be-
tween two adjacent subunits, and residues from both subunits
contribute to interaction with the ligand. An  subunit always
contributes the principal side, and various subunits can con-
tribute to the more variable complementary side of the
interface.
It has been very difficult to obtain detailed structural infor-
mation about these receptors. Electron microscopy analysis has
resulted in a 4-Å resolution model of the transmembrane part,
which provided insight into the structural and functional as-
pects of channel opening (6). Structural information about the
ligand binding domains and the subunit interfaces has ex-
panded upon discovery and crystallization of acetylcholine-
binding protein from the snail Lymnaea stagnalis (Ls-AChBP)
(7, 8), a soluble homologue of the nAChR ligand binding do-
main. This crystal structure has been embraced as an excellent
model for analyzing the ligand binding domains of nAChR
(9–12) GABA (13–14), glycine (15), and 5-HT3 (16) receptors.
The application of AChBP as a LGIC model is further sup-
ported by recent experiments showing that AChBP can be
functionally coupled to the transmembrane region of a 5-HT3
receptor (17). The recent crystal structures of Ls-AChBP in
complex with nicotine and carbamylcholine have elucidated the
molecular contacts between ligand and protein and are in ex-
cellent agreement with biochemical data obtained from nAChR
binding studies (18). These structures also emphasize the im-
portance of obtaining different high resolution AChBP struc-
tures for improving modeling studies as they reveal movements
within the protein that are difficult to infer from homology
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models. The discovery of AChBP has led to the identification
and biochemical characterization of AChBP from the snail
Aplysia californica (Ac-AChBP) that shows distinct ligand
binding properties compared with that of Ls-AChBP (19).
Here we present the pharmacology and x-ray structure of
Bulinus truncatus AChBP (Bt-AChBP) and use it to analyze
differences in sequence and the concomitant diversity in ligand
binding characteristics. We noticed earlier that sequence diver-
sity between subunits is most notable at the subunit interfaces,
which lack conserved sites of interaction apart from the ligand-
binding site (8). Here we show that these differences in subunit
interface have a significant effect on the stability of the AChBP
pentamers. Using isothermal titration calorimetry (ITC), we
have analyzed ligand binding to Bt-AChBP and Ls-AChBP/Bt-
AChBP substitution mutants to identify the residues that are
responsible for differences in ligand binding affinity. Because
the variations in interface contacts and ligand binding are
similar to those observed between mammalian receptor sub-
types, they provide an essential analysis to unravel the con-
served scaffold of the LGIC ligand binding domains.
EXPERIMENTAL PROCEDURES
Cloning of B. truncatus AChBP—Live B. truncatus specimens were
obtained from the river Nile delta (Egypt) and subsequently cultured in
the laboratory under standard (Lymnaea) freshwater conditions.
Poly(A) RNA was isolated from the central nervous system. cDNA
was generated by reverse transcription using the primer RoRi-(dT17)
(5-ATCGATGGTCGACGCATGCGGATCCAAAGCTTGAATTCGAGC-
TCT(dT17)-3). For the identification of Bt-AChBP homologues, a nested
PCR strategy was adopted using degenerate oligonucleotides designed
to match conserved regions of Ls-AChBP and the nAChRa7 as well as
to unique AChBP sequence features. Two nested primers were de-
signed, BABP1 (5-GA(A/G)AG(C/T)GGNGCNACNTG(T/C)(C/A)G-
NAT(A/T/C)AA-3) and BABP2 (5-CGGAATTCTG(T/C)(C/A)GNAT(A/
T/C)AA(A/G)GTNGGNAG(C/T)TGG-3). A first PCR was performed
using 50 pmol of BABP1 primer in combination with 50 pmol of the first
adaptor primer Ro (5-ATCGATGGTCGACGCATGCGGATCC-3) on
the RoRi-generated cDNA template in a volume of 100 l for 40 cycles
(94 °C, 30 s; 63 °C, 45 s; 72 °C, 2 min). To increase specificity, a second
round of nested amplification was carried out on 1% of the previous
PCR reaction mixture using 50 pmol of BABP2 in combination with 50
pmol of nested adaptor primers Ri (5-GGATCCAAAGCTTGAATTC-
GAGCTCT-3) under identical conditions as described above. PCR prod-
ucts from the reaction were separated on agarose gel, and DNA prod-
ucts of appropriate size were isolated, subcloned in pBluescript KS()
(Stratagene), and sequenced. The full-length Bt-AChBP cDNA was
obtained by 5 rapid amplification of cDNA ends on cDNA templates
derived from Bulinus central nervous system using a cloning and se-
quence strategy as described earlier (20). Possible DNA sequence errors
introduced by PCR amplification were eliminated by sequence compar-
ison of three independently generated PCRs products.
In Situ Hybridization—Localization of Bt-AChBP mRNA was stud-
ied in sections of the central nervous system with in situ hybridization
using digoxigenin-UTP-labeled cRNA probes. Tissue was fixed in 1%
paraformaldehyde and 1% acetic acid for 36 h and embedded in paraf-
fin. Sections of 5-m thickness were adhered to SuperFrost-Plus slides
(21). After dewaxing, sections were fixed with 2% paraformaldehyde in
phosphate-buffered saline at room temperature for 4 min and 1% hy-
droxylammonium chloride in phosphate-buffered saline for 15 min.
Next, the slides were dehydrated in alcohol and air-dried. Digoxigenin-
labeled cRNA probes (sense and antisense) were made on 40 ng of a
PCR fragment corresponding to positions 230–511 of the Bt-AChBP
open reading frame that included T3 and T7 RNA polymerase promot-
ers. In vitro transcription was performed using either T3 or T7 RNA
polymerase containing 1 mM GTP/ATP/CTP, 0.65 mMUTP, and 0.35 mM
digoxigenin-11-UTP. Reactions were stopped after 2 h of incubation,
treated with 20 units of DNase I (Roche Applied Science) at 37 °C for 10
min, hydrolyzed with 0.2 M NaOH on ice for 30 min, neutralized with
Tris-HCl, and ethanol-precipitated. About 10% of the cRNA formed was
added per slide. Hybridization was done in 60% formamide at 50 °C for
16 h, washed in 2 SSC (1 SSC  0.15 M NaCl and 0.015 M sodium
citrate), 50% formamide for 15 min 55 °C, 100 ng/ml RNase A for 25
min, 2 SSC, 50% formamide at 55 °C for 3  15 min, and 2 SSC at
room temperature for 2  5 min. Next, the digoxigenin was visualized
using an alkaline phosphatase-labeled antibody directed to digoxigenin.
Protein Preparation—The Bt-AChBP gene including its signal se-
quence was expressed in baculovirus using the pFastbac I vector ac-
cording to Invitrogen protocols. Secreted AChBP was purified 72 h after
infection of SF9 cells as described for Ls-AChBP (18). The yield was 5
mg/liter, giving a single molecular species with anMr of250,000 in gel
filtration and multi-angle laser light scattering experiments using a
Wyatt Technology miniDAWN on-line with a Superdex 200 gel filtra-
tion column. SDS-PAGE and mass spectrometry analysis revealed the
presence of a single subunit species (Mr 23,758), indicating that purified
Bt-AChBP exists as a stable decamer. The calculated mass of the
monomer is 22,938, suggesting that glycosyl groups of Mr  820 are
attached to the potential glycosylation sites Asn-21 and Asn-26.
Crystallization—Crystals of Bt-AChBP were grown at room temper-
ature using the hanging drop method. The best crystals were obtained
at relatively low protein concentrations (0.2–0.5 mg/ml). Orthorhombic
crystals (C2221) of AChBP were grown in a solution of 2.0 M ammonium
sulfate, 200 mM lithium sulfate, and 0.1 M CAPS, pH 10.5. Cell con-
stants are: a 76.95 Å, b 219.02 Å, c 166.97 Å, and 1 pentamer per
asymmetric unit.
Structure Solution and Refinement—We collected data at ID14 EH4
at the European Synchrotron Radiation Facility (Grenoble, France).
MOSFLM (22) was used for indexing of data and designing the optimal
data collection strategy. Data were processed and scaled using DENZO
and SCALEPACK (23). Programs in the CCP4 suite were used to build
and refine the model. An initial model was built with the AMORE
molecular replacement program (22) using the HEPES-bound Ls-
AChBP pentamer (18) as the search model. Automated model building
was performed using ARP/wARP (24). The structure was rebuilt in O
(25) and refined with REFMAC, including TLS refinement (26). The
final model has been refined without any non-crystallographic symme-
try restraints. CAPS buffer molecules were built and refined at the final
stages of refinement. A CAPS buffer molecule could be built within 4
ligand-binding sites in the asymmetric unit (56 atoms in total). In one
of these sites the CAPS molecule was estimated to have 75% occu-
pancy, whereas density in the 5th site indicated the presence of solute
molecules rather than a CAPS molecule. Water molecules were found
using the ARP/wARP program (24) in combination with REFMAC
cycles.
Structure Analysis—Optimized multiple superposition was obtained
with LSQMAN (27). Structure analysis was performed with CCP4
programs (22) and central nervous system (28). Interface analysis was
performed with CCP4 programs and the EBI web server. The figures
were made with ESPript (29) and PyMol (W. L. DeLano, San
Carlos, CA).
Circular Dichroism—CD spectra were recorded in the far UV range
(195–260 nm) in quartz cells with a 1-mm path length and in the near
UV range (250–320 nm) in 5-mm-path length cells on a Jasco (Tokyo,
Japan) J-810 CD spectropolarimeter. Proteins were dialyzed against 20
mM sodium phosphate buffer, pH 8.0, and diluted to 0.4 and 2 mg/ml for
CD measurements in the far UV and near UV region, respectively.
Thermal stability was monitored by collecting spectra at different tem-
peratures between 25 and 90 °C. Solutions were equilibrated for 5 min
at selective temperatures before spectra were recorded.
Bungarotoxin Binding—Biotinylated bungarotoxin (16 M) was in-
cubated with AChBP (3 M) in 50 l of buffer containing 100 mM NaCl
and 20 mM Tris, pH 8.0, for 1 h at room temperature. 25 l of strepta-
vidin beads were added to the solution to precipitate -bungarotoxin-
(AChBP). Supernatant was removed, and beads were washed 3 times
with 100 mM NaCl and 20 mM Tris, pH 8.0. Proteins were eluted from
the beads by boiling in sample buffer and subsequently loaded on
SDS-PAGE. Protein bands were visualized by Coomassie staining.
Isothermal Titration Calorimetry—ITC experiments were performed
with the VP-ITC MicroCalorimeter (MicroCal, Inc.) in 100 mM NaCl, 25
mM phosphate buffer, pH 8.0, as described previously (18). Data points
were fitted to a model describing a single type of binding site using
software supplied by the ITC manufacturer.
RESULTS
Identification and Cloning of B. truncatus AChBP—We an-
alyzed B. truncatus central nervous system-derived cDNA tem-
plates for the presence of AChBP homologs using a PCR strat-
egy and degenerate oligonucleotides designed to target
potentially sequence-conserved regions in Ls-AChBP. The ob-
tained sequences were made full-length by 5 and 3 rapid
amplification of cDNA ends. Two AChBP homologs, Bt-AChBP
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and Bt-AChBP-2, were identified with 96% sequence identity.
Bt-AChBP is expressed in glial cells of the central nervous
system of the animal (Fig. 1D), similar to the expression of
Ls-AChBP (7). In Fig. 1A a sequence comparison of the ACh-
BPs and members of the Cys-loop family show that Bt-AChBP
shares 41% sequence identity with Ls-AChBP, 29% with the
recently characterized Ac-AChBP (19) (Fig. 1C), and 13–25%
with LGIC subunits.
FIG. 1. Comparison of Bt-AChBP to other AChBPs and LGIC receptors. A, ClustalX protein sequence alignment of Bt-AChBP, AChBP
homologs and subunits of the Cys-loop family of LGICs. Alignment is shown from the first residue of Ls-AChBP to the last of Ac-AChBP.
Represented on top are the secondary structure elements of Bt-AChBP (, -helix; , -strand; , 310-helix). Indicated are residues of the principal
(yellow) and complementary (blue) components of the nicotinic ligand-binding site as well as positions different in Bt-AChBP types 1 and 2 (green).
Identical (red) and conserved (red letters) residues are marked. Stars indicate beginning and end of the conserved Cys-loop. B, phylogenetic analysis
of AChBP homologs and human Cys-loop family subunits. An unrooted tree was calculated on aligned protein sequences (as shown in panel A) by
the maximum likelihood method using Phylip (49). Bootstrap values of 1000 scrambled data sets are indicated at branches; sub-threshold bootstrap
value displayed in italic. C, identity table of AChBP homologs representing the percentages of identical residues on corresponding positions. Hs,
Homo sapiens; Bt, B. truncatus; Ls, L. stagnalis; Ac, A. californica.D, in situ hybridization on Bulinus central nervous system showing the presence
of Bt-AChBP transcripts in glial cells (solid arrowhead) and not in neurons (open arrowhead). Scale bar, 20 mm. No signal was observed for sense
probe hybridizations.
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The Bulinus protein and the other AChBPs contain a func-
tionally conserved nAChR ligand-binding site. All residues on
the principal side (loop A, Tyr-88; loop B, Trp-142; loop C,
Tyr-X-Cys-Cys-X-Tyr motif) are present, and the residues on
the complementary side are conserved (loop D, Trp-51 and
Gln-53) or fall within the sequence variation that is observed in
nicotinic receptors (loop E). Residues of the subunit interface,
however, show very little conservation in Bt-AChBP and the
other AChBPs. This variability is also found between members
of the LGICs (8), suggesting that the conserved ligand-binding
site and the monomer interface have evolved as discrete parts
during evolution.
We produced Bt-AChBP and Bt-AChBP-2 in the yeast Pichia
pastoris and in a baculovirus expression system in Sf9 insect
cells. Although the two Bt-AChBPs share 96% sequence iden-
tity with conservative substitutions, Bt-AChBP-2 did not ex-
press well in a heterologous system, and we decided to focus on
the characterization of Bt-AChBP. In solution, the purified
protein behaves as a decamer, as shown by gel filtration and
multi-angle laser light scattering (data not shown), in contrast
to the Lymnaea protein, which behaves as a pentamer. How-
ever, the decamer observed in solution for the Bulinus protein
is also seen for the Lymnaea protein in the crystallographic
packing in most crystal forms.
Crystal Structure of Bt-AChBP—The Bt-AChBP crystal
structure was determined at 2.0 Å by molecular replacement
with the Ls-AChBP structure as a search model (Fig. 2). In
contrast to all Ls-AChBP structures, the crystallographic data
were excellent and did not require non-crystallographic sym-
metry (Table I). Refinement resulted in an R-factor of 20.9%
and free R-factor of 24.9%, in which residues Gln-1–Lys-203
from each subunit could be built into the electron density.
There are two potential N-glycosylation sites at Asn-21 and
Asn-26, but weak sugar density indicates that only Asn-26 is
glycosylated. The r. m. s. deviation between subunits is be-
tween 0.25 and 0.45 Å on 196 Cs, excluding the major varying
region (residues 154–161) in the F-loop.
Bt-AChBP was crystallized in the presence of CAPS buffer,
pH 10.5, and a CAPS molecule could be built with confidence
into the electron density in four of five binding sites. Three sites
are fully occupied by CAPS, whereas the fourth site shows a
lower occupancy (75%). The electron density at the fifth site
indicates a low occupancy of CAPS and the presence of solute
molecules. Interestingly, double conformations of Tyr-88 were
observed in the two binding sites with the lower occupancy of
CAPS, illustrating the movement of the tyrosine side chain
upon ligand binding. This ligand-dependent change is similar
to that observed for Tyr-89 in Ls-AChBP (18). After superposi-
tion of Bt-AChBP and Ls-AChBP with nicotine bound, CAPS
and nicotine closely superimpose with positive nitrogen posi-
tions agreeing within 1.1 Å. No CAPS binding could be identi-
fied in bungarotoxin competition studies and ITC, indicating
that the binding affinity is very weak. Contacts of the CAPS
molecule are given in Fig. 3, showing hydrogen bond interac-
FIG. 2. The crystal structure of Bt-AChBP. The pentamer structure in the side and top view of Bt-AChBP (A) compared with Ls-AChBP (B)
in a schematic representation with each monomer in a different color. In the side view the N-terminal region (indicated by N) is at the top, and
the nAChR transmembrane domain would be at the bottom near the C terminus (indicated by C). C, side view of a superposition of one monomer
of Bt-AChBP (wheat) on Ls-AChBP (blue).
TABLE I
Crystallographic parameters
Space group C2221
Unit cell parameters
a 77.0
b 219.0
c 167.0
Resolution (Å) 50–2.0
Redundancy 5.1 (3.4)a
Rmerge (%)
b 12.9 (77.9)
I/sigI 12 (1.7)
Mosaicity (°) 0.74
Completeness (%) 98 (89)
Refinement
Resolution (Å) 12–2.0
Reflections 88,439
Atoms 8,566
R factor (%)c 20.9
Rfree (%)
d 24.9
r.m.s. bonds (%) 0.013
r.m.s. angle (o) 1.523
a Values in parentheses correspond to the highest resolution data
shell (2.07–2.0 Å).
b Rmerge  I  I	/I	.
c R-factor  Fobs  Fcalc/Fobs.
d Rfree  R-factor for 5% of reflections that were not used in refine-
ment.
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tions with the carbonyl oxygen of Trp-142 to the positive charge
in the buffer, as was observed for other agonists. Two addi-
tional hydrogen bonds are seen to the sulfate portion of
the molecule.
Structural Comparison to Ls-AChBP—The structure of Bt-
AChBP is remarkably similar to that of Ls-AChBP despite the
low sequence conservation. All secondary structure elements
are conserved, and most of these are of equal length (Fig. 4A) in
the two snail AChBPs. In automated superposition of the indi-
vidual domains using LSQMAN, a core of 170–180 C atoms
superimposes, with an r.m.s. density of 1.2 Å against each of
the three high resolution structures of Ls-AChBP (18).
Comparison of the entire AChBP pentamers, based on a
superposition of the C atoms of the core residues of each
subunit, shows that differences between both AChBPs are lim-
ited to structural variation within each subunit itself rather
than a change in the relative orientation of the subunits. The
most pronounced differences are at the “top” of the molecule,
furthest from the membrane interface in nAChRs (Fig. 2B).
There the N-terminal helix is differently oriented, and the
2-3 region is reorganized and includes a longer 310 helix. The
decamer of the Bulinus protein is formed by a crystallographic
2-fold axis, stacking the pentamers with their N termini to each
other. Residues that are responsible for decamer formation are
not conserved in Ls-AChBP. These include 10 salt bridges
between residues Arg-3 and Glu-13 in all Bt-AChBP subunits.
The loop 9 (or F-loop region, residues 155–167) that is disor-
dered in most of the Ls-AChBP subunits also has a different
structure in the Bulinus protein.
The most striking difference between Ls- and Bt-AChBP is
the conformation of a series of critical loops on the side of the
pentamer that would be close to the transmembrane region in
the LGICs, loops 2 (residues 41–44) and 7 (Cys-loop, residues
122–135), and the C terminus (loop 11, residues 200–203) (Fig.
2B). All these loops are oriented differently with respect to the
AChBP core between the two species due to rigid body shifts.
These rigid body shifts are intriguing, and several explanations
for this shift in orientation can be given. They could be an
intrinsic feature of the Bt-AChBP structure, or alternatively,
they could be due to the high pH of the crystallization buffer or
the result from CAPS binding.
Pentamer Interface and Stability—In our initial analysis of
the Ls-AChBP structure we noticed that the interface between
monomers was poorly conserved between different LGIC sub-
families and that most of the conserved residues contribute to
the hydrophobic core of the monomer (8). The availability of a
second crystal structure provides the opportunity to analyze
what the effect is of such a variable interface. This is essen-
tial because these interfaces harbor the conserved ligand-
binding site. In the pentamer structure each monomer con-
tributes to two separate interfaces. Thus, the A subunit
contributes its so-called “principal side” to the AB interface
and its “complementary side” to the EA interface. Below the
alignment of Fig. 4A, an analysis of the monomer A residues
in the AB (indicated by B) and the EA interface (indicated by
E) are given for the two molluscan AChBP crystal structures.
From this comparison it is clear that, although the same
loops are involved in the protein-protein interface, the actual
contacts are completely different. The only residues that
make similar contacts are found in the binding site. The
mapping of interface residues onto the surface of the mono-
mer shows that indeed the interfaces are very different (Fig.
4, B–E). However, the overall characteristics of these inter-
faces are highly similar in terms of size, hydrophobicity, and
accessible surface area.
To obtain a better understanding of the stability of the in-
terface, we used CD to compare the thermal stability of the
molluscan AChBPs. As expected, spectra recorded for Bt-
AChBP and Ls-AChBP at the far UV region show the charac-
teristics of a structure that is largely composed of -sheets (Fig.
5, A and B). They are similar to the spectrum obtained for the
monomeric ligand binding domain of the muscle -subunit from
mouse (30), reconfirming that the structures are very similar.
The spectra measured in the near UV region are indicative of
proteins with a well defined tertiary structure (Fig. 5, C andD).
The signals are attributable to phenylalanine, tyrosine, and
tryptophan residues as well as to disulfide bonds. The profiles,
however, are different, presumably due to differences in the
local environment of aromatic residues that influence the ab-
sorption of these residues.
From a series of spectra measured at increasing tempera-
tures (Fig. 5) we observed a significant difference in stability.
Ls-AChBP only starts to melt at 65 °C, whereas Bt-AChBP has
its transition between 50 and 55 °C. We could see the same
shift in both the far and near UV region. Because we do not
seem to lose the -sheet structure completely, it is likely that
the individual monomers do not unfold entirely and that the
transition that we observe primarily reflects the loss of the
multimeric structure. Thermal denaturation was irreversible
for both AChBPs (data not shown), indicating that refolding of
the multimeric state was not possible. The high stability of the
secondary structure upon heating has also been observed for
the ligand binding domain of the muscle -subunit from mouse
(30) and for other proteins containing a substantial number of
-strands (31).
Although Ls-AChBP is considerably more stable, it is diffi-
cult to attribute this to any specific structural parameter. In
the Ls-AChBP structure each interface has on average one
extra hydrogen bond and two additional salt bridges. However,
salt bridges are difficult to evaluate in the Bt-AChBP structure
due to the extreme pH (10.5) of the crystals. It is possible that
e.g. the pair of Asp-84 and Arg-101 on the principal and com-
plementary side, respectively, would form an additional salt
bridge at lower pH. The precise number of hydrogen bonds also
changes slightly between the different ligand-bound struc-
FIG. 3. CAPS binding to Bt-AChBP. A CAPS buffer molecule is
bound in the ligand-binding site of Bt-AChBP. A, LIGPLOT represen-
tation (50) showing CAPS contacts with subunit A (principal side) and
subunit B (complementary side). B, electron density of CAPS in ball-
and-stick model showing hydrogen bonds to the protein.
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tures, dependent on the position of residues that touch the
ligand. Altogether, the large differences in interface contact
make it difficult to assess the precise region that contributes to
the variation in stability.
Ligand Binding—Because the ligand-binding site is part of
the monomer interface, we next assessed differences in ligand
binding properties of Bt-AChBP and Ls-AChBP. We first de-
termined the binding curve of I125-labeled -bungarotoxin to
Bt-AChBP. In contrast to Ls-AChBP, Bt-AChBP does not bind
significantly to -bungarotoxin (data not shown). This is con-
firmed by the absence of Bt-AChBP-bungarotoxin complex
when biotinylated bungarotoxin was used in a pull-down assay
(Fig. 6A). Bt-AChBP contains a lysine at position 183, similar
to the human 2, 3, and 4 subunits that do not bind to the
toxin. NMR and mutagenesis studies have shown that nAChRs
that bind to -bungarotoxin have a tyrosine or phenylalanine
at this position (32–34) and that replacement of this tyrosine by
lysine completely prevents binding of -bungarotoxin (34, 35).
To obtain detailed insight in the ligand binding characteris-
tics of Bt-AChBP, we analyzed the binding to several ligands
using ITC. Bt-AChBP shows up to 10-fold higher affinity for
nAChR agonists when compared with Ls-AChBP (Table II).
The increase in affinity can be attributed to a more favorable
enthalpy change (
H) even though the change in entropy (
S)
has a more unfavorable contribution to the affinity. Because
the 
H value represents the strength of molecular interactions,
Bt-AChBP apparently forms more and/or tighter interactions
with these agonists.
The nAChR antagonist d-tubocurarine is bound with very
high affinity to Ls-AChBP (Table II, Fig. 6B). In contrast to
agonist binding, however, 
S then has a favorable effect on
binding, whereas the contribution of 
H is 2-fold reduced.
Binding of d-tubocurarine to Bt-AChBP also appears to be
largely determined by 
S, but thermodynamic parameters can-
not be measured accurately because of the very small heat
signals that are recorded (Fig. 6C).
FIG. 4. The subunit interface. A, sequence alignment showing Bt- and Ls-AChBP conservation, secondary structures, and residues involved
in subunit interfaces. These are indicated below the alignment, with B if located on the principal side of the interface and with E if located at
complementary side of the interface, colored in red if within hydrogen-bonding distance or in black if within van der Waals contact to the other
subunit; residues forming the principal binding site (yellow boxes) and the complementary binding site (blue boxes) are indicated. The figure is
generated with ESPript (29). B–E, opening up of subunit interface. Residues that are part of the interface are shown in a surface representation
and are colored by atom type (red, oxygen; blue, nitrogen; white, carbon; green, sulfur), with the ligand shown in ball-and-stick of the Bt-AChBP
principal side (B) and Bt-AChBP complementary side (C). D, Ls-AChBP principal side; E, Ls-AChBP complementary side.
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Modulation of Binding by Variation of the Complementary
Binding Site—Because the ligand affinities for Bt-AChBP and
Ls-AChBP show a 5–10-fold difference, this leaves the possi-
bilities that these differences are attributable to the earlier
measured dissimilarities in interfaces and stability or that they
are directly caused by a discrepancy in residues within the
ligand-binding site itself. Because only three ligand binding
residues are different between the two AChBP species, we
tested whether mutation of these residues in the Lymnaea
protein would generate an increase in affinity similar to that
observed for Bt-AChBP. Therefore, we mutated the side chains
of Arg-104, Leu-112, and Met-114 in the complementary bind-
ing site of Ls-AChBP into the corresponding residues in Bt-
AChBP (Val-103, Ile-111, and Val-113, respectively) (Fig. 7B)
and studied the binding properties using ITC (Table II).
The Ls-AChBP-M114V and Ls-AChBP-R104V substitution
variants display a selective increase in affinity for nicotine
(Table II), whereas the affinity of the Ls-AChBP-L112I mutant
is lower than either Ls-AChBP or Bt-AChBP. The effect of the
mutants on nicotine binding can be explained by analysis of the
AChBP structures. The negative effect of the L112I substitu-
tion seems to be caused by loss of hydrophobic contact, because
Ile-111 in the Bt-AChBP structure is positioned away from the
ligand (Fig. 7B), whereas the leucine side chain makes good
contact with both nicotine and acetylcholine (18). The opposite
effect is true for the Ls-AChBP-R104V mutation; the extended
side chain of Arg-104 does not contact nicotine, but the
branched side chain of the valine provides a beneficial hydro-
phobic contact to the CAPS binding in Bt-AChBP and would
also do so for nicotine. The positive effect of the M114V
mutation can be explained by nicotine forcing the methionine
side chain C into an unusual rotamer position to avoid a
direct clash with nicotine (18). Thus, the substitution of a
smaller side chain is beneficial for nicotine binding. The
critical role of residue 114 in ligand binding affinity is further
stressed by the fact that mutation of M114V causes a 5-fold
increase in affinity for d-tubocurarine (Table II), whereas
M114Y and M114T substitutions reduce binding 6- and 11-
fold, respectively (36).
The effects of acetylcholine binding on mutations at the 112
and 114 position are in line with the structural analysis above,
but the double mutant result cannot be simply explained. In
addition, the strongly detrimental effect of the R104V mutant
and the resulting effect on the triple mutant cannot be explained
from the structural analysis. One possibility may be that loss of
a salt bridge between Arg-104 and Glu-147 (Gln-148 in
Bt-AChBP) in the R104Vmutant is unfavorable for acetylcholine
binding. Alternatively, additional residues/regions (e.g. F-loop)
outside the binding site could have ligand-specific contributions
that cannot be easily predicted from our structures.
FIG. 5. Stability of AChBPs upon
heat denaturation. CD spectra were re-
corded at increasing temperatures (25–
90 °C) in the far UV region (195–260 nm)
for Bt-AChBP (A) and Ls-AChBP (B). CD
spectra in the near UV region were re-
corded between 250–320 nm for Bt-
AChBP (C) and Ls-AChBP (D). All graphs
contain a selection of the spectra that
were recorded at various temperatures.
Temperatures (in °C) are indicated for
each spectrum that is displayed.
FIG. 6. Ligand binding to Bt-AChBP. A, -bungarotoxin pull-down experiment on purified Ls-AChBP and Bt-AChBP as described under
“Experimental Procedures.” Samples of purified Ls-AChBP and Bt-AChBP (lanes 1 and 3, respectively) were incubated with biotin-labeled
-bungarotoxin and streptavidin beads. Proteins that are bound to the beads after incubation with Ls-AChBP and Bt-AChBP (lanes 2 and 4,
respectively) were eluted from the beads by boiling in sample buffer and loaded on SDS-PAGE. Protein bands were visualized by Coomassie Blue
staining. ITC binding curves of d-tubocurarine binding to Ls-AChBP (B) and Bt-AChBP (C) are shown. The top panels show the heat response upon
each injection of d-tubocurarine into AChBP solution. Data points obtained from integration of the heat signals are plotted in the bottom panels
and fitted to a model describing a single type of binding site.
Crystal Structure of B. truncatus AChBP 26463
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
The triple mutant Ls-AChBP R104V/L112I/M114V shows a
clear gain-of-affinity for binding both nicotine and d-tubocu-
rarine and mimics the affinities observed for the Bulinus
protein. Because these mutations affect van der Waals con-
tacts, we analyzed the effect of the substitutions on hydro-
phobic contact with the ligands using ITC. We measured 
H
of nicotine and acetylcholine binding to the various AChBPs
at selective temperatures. 
H is linearly dependent with
temperature (Fig. 7C), and the slope of the line represents
the change in heat capacity (
Cp). Because a negative 
Cp
value is an indication of the hydrophobic contribution to
ligand binding (37), Bt-AChBP has more van der Waals con-
tact to nicotine and acetylcholine than Ls-AChBP (Fig. 7C,
Table II). The hydrophobic contribution to nicotine binding in
the gain-of-affinity Lymnaea triple mutant AChBP has be-
come equivalent to that in the Bt-AChBP. Thus, these three
mutations contribute to make the Ls-AChBP -binding site
resemble the Bt-AChBP. However, the remaining differences
in entropic and enthalpic contribution as well as the acetyl-
choline binding effects show that regions outside the imme-
diate binding site also contribute to the affinity.
DISCUSSION
In this study we cloned the AChBP gene from the snail
B. truncatus and compared the structural and pharmacological
properties of Bt-AChBP protein to that of Ls-AChBP. Bt-
AChBP is expressed in glial cells of the central nervous system
FIG. 7. Substitution of binding site residues R104V, L112I, and M114V. Opening-up of the AChBP ligand-binding site shows the principal
(A) and complementary (B) binding site when Bt-AChBP (yellow, wheat) and Ls-AChBP (blue, slate) are superimposed. CAPS and nicotine
molecules (pink, carbons) are shown; residue numbering is shown in dark red for Bt-AChBP/Ls-AChBP in the principal side (A) and pink/blue for
Bt-AChBP/Ls-AChBP residues that have been exchanged in Ls-AChBP (B). C, titration of nicotine with Ls-AChBP (E), Bt-AChBP (●), Ls-AChBP-
L112I (‚), Ls-AChBP-M114V (Œ), Ls-AChBP-R104V (f), Ls-AChBP-R104V/L112I/M114V () at 4, 10, 22, and 30 °C. 
H is plotted against the
temperature, and 
Cp is obtained from the slope of the linear fittings.
TABLE II
Thermodynamic parameters of AChBP-ligand interaction
AChBP-ligand interactions were studied using isothermal titration calorimetry. Data represent the mean (S.D.) of at least two separate
experiments. Dissociation constants (Kd) and thermodynamic parameters 
H (enthalpy change) and 
S (entropy change) were determined by
titration of ligands into AChBP in 100 mM NaCl, 25 mM phosphate buffer, pH 8.0, at 22 °C. 
 Cp (heat capacity) was calculated from the slope of
linear fits of 
H versus temperature (T) as shown in Fig. 7C.
Protein Ligand Kd 
H T
S 
Cp
nM kcal mol1 kcal mol1 cal mol1 K1
Ls-AChBP Nicotinea 45  2 14.5  0.2 4.5  0.1 207  15
Bt-AChBP Nicotine 8  4 17.5  0.3 6.5  0.6 383  10
Ls-R104V Nicotine 22  1 14.1  0.1 3.3  0.1 270  1
Ls-L112I Nicotine 253  28 11.4  0.2 2.5  0.1 146  9
Ls-M114V Nicotine 18  4 13.9  1.6 4.3  0.2 225  2
Ls-L112I/M114V Nicotine 59  9 12.7  0.1 3.0  0.1 NDb
Ls-R104V/L112I/M114V Nicotine 12  1 15.0  0.3 4.1  0.3 345  19
Ls-AChBP Acetylcholinea 823  40 12.5  0.1 4.2  0.3 126  13
Bt-AChBP Acetylcholine 153  23 16.3  0.4 7.0  0.5 327  3
Ls-R104V Acetylcholine 10,000 ND
Ls-L112I Acetylcholine 2870  396 12.3  0.6 4.8  0.7 ND
Ls-M114V Acetylcholine 1710  226 16.3  0.8 8.6  1.5 ND
Ls-L112I/M114V Acetylcholine 1120  47 9.5  0.8 1.5  0.9 ND
Ls-R104V/L112I/M114V Acetylcholine 10,000 ND
Ls-AChBP Carbamylcholinea 7575  430 13.4  0.4 6.5  0.6 ND
Bt-AChBP Carbamylcholine 721  283 14.1  0.5 5.7  0.3 ND
Ls-AChBP d-Tubocurarine 42  3 6.9  0.6 3.0  0.4 ND
Bt-AChBP d-Tubocurarinec 20 1.4 8.9 ND
Ls-R104V d-Tubocurarine 26  5 5.9  0.1 4.4  0.2 ND
Ls-L112I d-Tubocurarine 11  4 5.9  0.1 4.9  0.2 ND
Ls-M114V d-Tubocurarine 12  4 9.2  0.3 1.5  0.6 ND
Ls-L112I/M114V d-Tubocurarine 11  3 5.0  0.5 5.8  0.4 ND
Ls-R104V/L112I/M114V d-Tubocurarine 20  2 4.3  0.2 6.1  0.1 ND
a Data were taken from Celie et al. (18).
b ND, not determined.
c Values for d-tubocurarine binding are an approximation, as explained under “Ligand Binding.”
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of the animal (Fig. 1D). This is similar to the expression of
Ls-AChBP, which is functionally implicated in the glial mod-
ulation of cholinergic synaptic transmission (7). Thus, we
expect that the function of this protein is conserved. It is
intriguing, however, that Bt-AChBP appears to be present as
a stable “double pentamer” in solution in contrast to pentam-
eric Ls-AChBP (8) and Ac-AChBP (19). Whether Bt-AChBP
also behaves as a double pentamer in vivo remains to be
established.
According to sequence identity, Bt-AChBP is more closely
related to Ls-AChBP than Ac-AChBP (sequence identity be-
tween Bt-AChBP and Ls-AChBP is 41 versus 29% between
Bt-AChBP and Ac-AChBP). This might be expected given the
evolutionary distance between species (Lymnaea versus Buli-
nus estimated at 15 million years and Lymnaea (Bulinus) ver-
sus Aplysia at 600 million years).
It is interesting to compare the rate of evolution of the
AChBPs with that of nicotinic receptor subunits in these
species. The two known Aplysia nAChR subunits (accession
numbers AAL37250 and AAL78648) share 47–86% sequence
identity with nAChR subunits identified from Lymnaea cen-
tral nervous system.2 Thus, the AChBPs show significantly
larger diversity (29%) than their receptor counterparts
(47%), indicating that the evolutionary pressure on conser-
vation of the AChBP sequence is apparently less than for the
nicotinic receptors.
Despite the diversity between Bt-AChBP, Ls-AChBP, and
Ac-AChBP, all three AChBPs have maintained a similar level
of sequence identity (11–28%) with the extracellular domains of
all Cys-loop family members, indicating that the evolutionary
pressure has preserved a minimal sequence scaffold between
the entire LGIC family and AChBPs. Although the sequence
conservation between Ls-AChBP and Bt-AChBP is low, the
structure of Bt-AChBP is very similar to that of Ls-AChBP.
This is an important validation for many modeling studies of
various LGIC ligand binding domains that have used Ls-
AChBP as a starting model. The comparison also reveals which
regions are most variable in structure and provides alternative
conformations for these variant regions. Residues of the sub-
unit interface have not been conserved in Bt-AChBP and the
other AChBPs as we noted before for the LGICs (8) except for
the ligand binding residues. Apparently, the conserved ligand-
binding site and the monomer interface form separate entities
during evolution.
The changes in subunit interface contacts in Bt-AChBP and
Ls-AChBP have an effect on protein stability (Fig. 5). This may
also be the case for the nAChR ligand binding domains, be-
cause expression of these domains has proven remarkably dif-
ficult, and in many cases a mixture of monomers, dimers, and
multimers was obtained (38, 39). Apparently the mode of pen-
tamer formation is poorly conserved, and these extracellular
domains may not have preserved the ability to form stable
pentamers in the absence of their respective transmembrane
regions. It will be useful to analyze the AChBP structures for
regions that could improve the formation of stable pentamers
in nicotinic structures.
The gain-of-affinity observed for nicotine binding to Ls/Bt-
AChBP mutants indicates that residues 104, 112, and 114
(Ls-AChBP numbering) located in the ligand-binding site itself
are mainly responsible for the difference in binding affinity.
The contribution of these residues to ligand binding is compat-
ible with altered binding capacities induced by mutagenesis of
corresponding residues in nAChRs (40, 41). Our results for
acetylcholine binding, however, imply that alternative residues
outside the binding site also contribute to ligand binding. These
may be part of the subunit interface but could also be located in
other parts of the protein.
Binding of nAChR agonists to AChBP involves a large favor-
able enthalpy contribution that is counteracted by an unfavor-
able change in entropy. Binding of the nAChR antagonist d-
tubocurarine in contrast is mediated by favorable changes in
both enthalpy and entropy (Table II). The opposite effect of 
S
on agonist versus antagonist binding has also been reported for
the nAChR receptor when ligand binding was analyzed at
various temperatures using membrane homogenates that con-
tain nAChRs (42, 43) and by measuring ligand-induced muscle
contraction of denervated diaphragm (44, 45). A similar effect
has been described for other members of the LGIC family and
also for a number of G-protein-coupled receptors (43). Although
this thermodynamic discrimination appears to be a common
feature in ligand-receptor interaction, the mechanism underly-
ing this phenomenon is not well understood. It does tell us,
however, that the conformational changes upon ligand binding
to AChBPs have the same character as binding to the nicotinic
receptors, although the switch from enthalpy- to entropy-
driven for agonist and antagonist binding is less dramatic
compared with that of the LGICs.
Formation of the subunit interface is essential for the gating
process in nAChR and other LGICs. Activation of the nAChR
induced by agonist binding involves a switch in the relative
orientation of subunits and induces channel opening (46). Al-
though AChBP lacks a transmembrane region and seems to
function as an acetylcholine buffer molecule rather than a
signal transducer (7), recent experiments using Ls-AChBP/5-
HT3A chimeras have shown that AChBP can be functionally
linked to a transmembrane domain (17). The fact that the
AChBP protein is capable of changing conformation in a pro-
ductive manner and providing the signal to open the receptor
illustrates the significance of analyzing AChBP structures in
addition to ligand binding capacities.
Because a high resolution structure of antagonist-bound
AChBP is not available, we cannot compare conformational
changes relative to our agonist-bound AChBP structures (18).
However, one of the most striking differences between Ls- and
Bt-AChBP is the conformation of a series of critical loops on the
“bottom side” of the pentamer that would be close to the trans-
membrane region in the LGICs. Although other properties like
crystallization conditions or variability in intrinsic protein
structures could be responsible for these differences, it may
also be possible that CAPS binding induces a change in these
loops. The CAPS buffer molecule is larger than the nicotinic
agonists that we have previously studied. Therefore, CAPS
may resemble an antagonist in its binding mode, and it is
possible that this pushes the structure into a state that ap-
proaches the “resting” state rather than the activated/desensi-
tized state that was observed for the Ls-AChBP structures.
Repositioning of the C-loop (residues 184–191, loop 10) upon
CAPS binding could induce the observed rigid body movement
of the loops 2, 7, and 11. This movement could be part of the
conformational change that occurs upon transition of the rest-
ing state into the activated state (46). These loops would con-
tact the transmembrane region in nAChRs and could, thus,
stabilize the open state of the channel. This agrees well with a
careful -value analysis (47) that these loops in nAChRs move
as rigid bodies during gating (48). The comparison between
resting and activated state by Unwin et al. (46) shows changes
in electron density that have the same direction as we observe
here. The changes that we observe, however, are much smaller
and indicate that we probably do not yet see the complete
2 P. van Nierop, S. Bertrand, D. Munno, Y. Gouwenberg, J. van
Minnen, J. D. Spafford, N. I. Syed, D. Bertrand, and A. B. Smit,
unpublished data.
Crystal Structure of B. truncatus AChBP 26465
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
features of the resting state. During the preparation of this
manuscript, a 4.2-Å crystal structure of Ls-AChBP in complex
with the nAChR-antagonist -cobratoxin was reported (51).
The structure shows conformational changes in C-loop and
F-loop compared with our agonist-bound Ls-AChBP structures
(18); however, no apparent changes were observed in loops 2, 7,
and 11. The observation that these loops do not change confor-
mation in the Ls-AChBP--cobratoxin structure is not under-
stood yet but might be caused by the tight non-crystallographic
symmetry that had to be maintained during refinement in
addition to the relatively low resolution.
For the analysis of the structural conversion that is at the
heart of the gating mechanism, it will be critical to have a good
understanding of the conserved features of the structural LGIC
scaffold to understand which regions are likely to be involved in
the conserved opening of the ion channel. Thus, the Bt-AChBP
structure presented here will provide critical help not only as
an improved template for drug design based on these struc-
tures but also to understand how the LGIC gating is
accomplished.
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